Citigroup Begins Coverage on Myovant Sciences (MYOV)
Citigroup began coverage on shares of Myovant Sciences (NYSE:MYOV) in a research note published on Thursday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $25.00 target price on the stock.
MYOV has been the topic of several other reports. Zacks Investment Research lowered Myovant Sciences from a buy rating to a hold rating in a research report on Tuesday, April 16th. ValuEngine lowered Myovant Sciences from a buy rating to a hold rating in a research report on Saturday, April 13th. Barclays upgraded Myovant Sciences from an equal weight rating to an overweight rating and raised their price target for the stock from $22.00 to $25.00 in a research report on Wednesday, February 13th. JMP Securities restated a buy rating and issued a $25.00 price target on shares of Myovant Sciences in a research report on Monday, February 11th. Finally, Evercore ISI started coverage on Myovant Sciences in a research report on Thursday, April 11th. They issued an outperform rating on the stock. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $26.83.
Shares of MYOV opened at $9.83 on Thursday. The company has a quick ratio of 3.51, a current ratio of 2.32 and a debt-to-equity ratio of 21.51. Myovant Sciences has a 52 week low of $8.75 and a 52 week high of $27.45.
Myovant Sciences Company Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
See Also: Why Net Income is Important to Investors
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.